It’s complicated: A case report on a COVID-19-positive HIV patient presenting with rhabdomyolysis and acute kidney injury

Allison Foster1,2, Zohaib Khan1, Aisha Siddiqui1, Sukhdev Singh1, Muhammed Atere3 and Jay M Nfonoyim4

Abstract
The SARS-CoV-2/COVID-19 pandemic in early 2020 has had a devastating impact on health systems around the world. While viral pneumonia remains the most common complication, reports are surfacing of cases with neurological, cardiac, and renal involvement. Even less is known about the implications in special high-risk populations. In this report, we discuss a unique case of an HIV-positive patient in New York City who presented with a 2-week history of worsening fatigue, cough, dyspnea, and myalgias and was found to have COVID-19 pneumonia and acute kidney injury. He was managed for severe uremic metabolic acidosis and electrolyte abnormalities with emergent hemodialysis and supportive therapy with subsequent improvement. Direct involvement of SARS-CoV-2 and pneumonia-induced rhabdomyolysis were identified as the precipitating factors of his acute kidney injury. The pathophysiologic mechanisms of acute kidney injury, SARS-CoV-2 renal tropism, and the impact of highly active antiretroviral therapy on COVID-19 pneumonia are discussed. We highlight the importance of clinician awareness of this potentially fatal complication of COVID-19 pneumonia, particularly in the HIV-positive population as early recognition and management can have favorable outcomes.

Keywords
Acute kidney injury, rhabdomyolysis, HIV, SARS-CoV-2, COVID-19

Introduction
In December 2019, SARS-CoV-2 a coronavirus caused an outbreak of viral pneumonia in Wuhan, China. The pandemic illness termed COVID-19 has now infected over 2 million people and has caused over 140,000 deaths worldwide.1 Recent studies have demonstrated that approximately 20%–40% of COVID-19 patients admitted to the intensive care unit (ICU) develop acute kidney injury (AKI).2,3 COVID-19-induced AKI presents with a more severe clinical course, particularly in the ICU setting, and is a negative prognostic factor with respect to survival. The mechanisms of kidney injury in COVID-19 infection have been hypothesized to be due to: (1) hypoperfusion-related injury of the renal tubule, (2) viral tropism for the kidney due to highly expressed angiotensin-converting enzyme (ACE)-2 receptors on podocytes and epithelial cells that are essential for viral uptake, and (3) cytokine-induced nephropathy.4 Reports are limited regarding patients on antiviral therapy who present with COVID-19 and subsequently develop kidney injury. Furthermore, a common complication of infection in HIV-positive patients is rhabdomyolysis which tends to precede AKI. HIV, overlapping infections, and antiviral medications used to treat HIV are known to be nephrotoxic. Considering the potential of nephrotoxicity of SARS-CoV2, we must attempt to distinguish the causes

1College of Medicine, American University of Antigua, New York, NY, USA
2Richmond University Medical Center, Staten Island, NY, USA
3Department of Internal Medicine, Richmond University Medical Center, Staten Island, NY, USA
4Chief of Critical Care and Clinical Medicine, Richmond University Medical Center, Staten Island, NY, USA

Corresponding Author:
Allison Foster, Richmond University Medical Center, 355 Bard Avenue, Staten Island, NY 10310, USA.
Email: AllisonF@auamed.net
and manifestations of kidney injury as well as the possibility of combined effects. Early recognition of COVID-19 and AKI in vulnerable populations is crucial to intervening early and lowering mortality.

**Case report**

A man in his 40s with a history of HIV on highly active antiretroviral therapy (HAART) and hypertension with a body mass index (BMI) of 34.9 presented to the Emergency Department (ED) after being seen at an urgent care clinic with hypotension and dyspnea. He visited his Primary Care Provider 2 weeks prior for fever, chills, and cough productive of grayish sputum; however, his symptoms persisted despite completing a course of azithromycin. During the interview, he denied recent travel or COVID-19 exposure. He endorsed fatigue, leg cramping, and poor appetite. CD4+ count and viral load were unknown to the patient. His vitals were unstable in ED with tachypnea (58 breaths/min) and hypotension (70/50 mmHg), heart rate of 91 beats/min, temperature of 37.1°C, and an oxygen saturation of 92% while on a non-rebreather mask at a flow rate of 15 L. On examination, he was in respiratory distress with decreased breath sounds in bilateral lung fields. The patients’ baseline creatinine was unknown at the time of presentation. The remainder of the examination was noncontributory; patient had good skin turgor and appropriate capillary refill. Vital signs for the duration of the visit are provided in Table 1.

Fluid resuscitation with IV normal saline was initiated. On re-examination, patient was hemodynamically stable with persistent tachypnea (28 breaths/min). He had multiple electrolyte abnormalities which are presented in Table 2. Inflammatory markers, troponin, and coagulopathy studies were not performed.

Urinalysis was significant for a white blood cell (WBC) >100/high-power field (HPF), red blood cell (RBC) 3/HPF, and pH 5.0. Bedside electrocardiogram (EKG) showed tachycardia (105 beats/min) and a prolonged QTc (518 ms) (Figure 1). A rapid nasopharyngeal swab collected was positive for SARS-CoV-2, prompting a myriad of presentations. With an estimated 14-day incubation period, most individuals show symptoms 4–5 days post-exposure. Symptomatic COVID-19 patients generally present with fever, cough, malaise, and shortness of breath, usually managed at home with supportive care. Other commonly reported symptoms are headache, sore throat, rhinorrhea, and diarrhea. Well-recognized risk factors for severe presentations include age, comorbidities such as lung disease, coronary artery disease, hypertension, diabetes, chronic kidney disease, and cancer.

In hospitalized patients, lymphocytopenia, elevation of liver enzymes, and CK are associated with ICU admission and higher mortality. This patient had an elevated white blood cell count and his CK was significantly elevated at...
Table 1. Vital signs.

|        | Day 1 | Day 1 | Day 1 | Day 1 | Day 2 | Day 2 | Day 2 | Day 3 | Day 4 | Day 4 | Day 5 | Day 5 | Day 6 | Day 7 | Day 7 |
|--------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
|        | 16:19 | 17:46 | 21:40 | 04:26 | 08:01 | 21:52 | 00:46 | 21:44 | 20:44 | 7:58  | 16:53 | 21:55 | 15:46 |
| HR     | 91    | 88    | 101   | 119   | 115   | 120   | 118   | 123   | 121   | 120   | 113   | 117   | 117   | 93    |
| RR     | 58    | 28    | 38    | 28    | 19    | 22    | 28    | 28    | 18    | 19    | 20    | 20    | 22    | 24    | 16    |
| BP     | 70/50 | 100/72| 84/50 | 89/67 | 136/71| 114/74| 109/66| 104/61| 133/90| 121/75| 115/68| 108/88| 140/90| 113/72| 125/63|
| O₂ Sat | 100   | 94    | 94    | 95    | 93    | 93    | 93    | 96    | 98    | 98    | 96    | 96    | 95    | 95    | 95    |
| T (°C) | 37.1  | 36.4  | 38.6  | 37.3  | 37.2  | 38.3  | 37.9  | 36.5  | 35.9  | 35.9  | 36.6  | 36.4  | 36.7  | 35.4  |       |
| BUN    | 151   | 157   | 119   | 126   | 112   | 111   | 109   | 98    | 92    | 75    | 69    | 62    | 48    | 33    | 30    |
| Cr     | 17.4  | 17.5  | 9.4   | 7.8   | 6.5   | 4.3   | 3.8   | 3.2   | 2.8   | 2.6   | 2.4   | 2     | 1.6   | 1.6   |       |
| Cr K   | 2185  | 3127  | 1785  | 1126  | 998   |       |       |       |       |       |       |       |       |       |       |

HR: heart rate; RR: respiratory rate; BP: blood pressure; O₂ Sat: oxygen saturation; T: temperature; BUN: blood urea nitrogen; Cr: creatinine; Cr K: creatine kinase.
2185 U/L on presentation. His chest X-ray revealed patchy infiltrates with peripheral, lower zone distribution and bilateral involvement, which is commonly seen in COVID-19 pneumonia.8

The patient presented with significant elevations in CK; his imaging revealed severe COVID-19 pneumonia, he was HIV positive, and he had a history of hypertension and was obese. Despite many risk factors and findings that would lend to poor prognosis, the patient was hospitalized for 7 days and required only a single round of hemodialysis. This lends the question of why his clinical course was brief compared with the average of 10 days for his age group and risk group.9 Recently, hemodialysis has been proposed as a prospective treatment for SARS-CoV-2 due to the affinity of the virus for renal parenchyma. Our patient did have a remarkable outcome following a sole round of hemodialysis via Shiley catheter. Future large-scale studies will be needed to provide insight to the efficacy of hemodialysis as a treatment for COVID-19.

In a recent histopathologic examination of COVID-19 patients,9 SARS-CoV-2-associated pulmonary lesions manifest as inflammation of the parenchyma and interstitium, with hyperplasia of the alveolar epithelium and formation of hyaline membranes. Damage was evidenced in areas outside of the lungs with lesions apparent in the cells of the immune, cardiac, hepatic, and renal systems.8 This tissue tropism is due to high expression of ACE-2 receptors on the alveoli. SARS-CoV-2 potentially gains entry into cells through binding of a spike protein on its envelope to ACE-2 receptors; uptake is via a clathrin-dependent endocytosis mechanism.10 Reports show that there are numerous ACE-2 receptors in podocytes and glomerular mesangial cells of the kidney.11 Given these findings, renal involvement of COVID-19 is not an unexpected phenomenon. In a retrospective study of patients from Wuhan

Table 2. Initial lab findings.

| Labs                        | Value         |
|-----------------------------|---------------|
| WBC                         | 15.6 µL       |
| Neutrophils                 | 88.5%         |
| Lymphocytes                 | 4.9%          |
| Serum osmolality            | 317 mOsm/L    |
| Na                          | 126 mmol/L    |
| K                           | 3.2 mmol/L    |
| Cl                          | 88 mmol/L     |
| Ca                          | 7.7 mmol/L    |
| Albumin                     | 3.5 g/dL      |
| HCO₃⁻                      | 9 mmol/L      |
| Blood urea nitrogen         | 151 mg/dL     |
| Creatinine                  | 17.4 mg/dL    |
| Anion gap                   | 29            |
| Lactic acid                 | 1.0           |
| AST                         | 18            |
| ALT                         | 50            |
| Uric acid                   | 13.8 mg/dL    |
| Glucose                     | 155 mg/dL     |
| pH                          | 7.12          |
| pCO₂                        | 25 mmHg       |
| pO₂                         | 28 mmHg       |
| Urine specific gravity      | 1.024         |
| Creatine kinase             | 2185 U/L      |

WBC: white blood cell; AST: aspartate transaminase; ALT: alanine transaminase.

Figure 1. Initial EKG.
from 17 January 2020 to 3 March 2020 with lab-confirmed COVID-19, 27% of patients exhibited acute renal failure. Post-mortem analysis showed severe acute tubular necrosis (ATN) and lymphocyte infiltration in the kidneys with SARS-CoV-2 NP antigen identified via immunohistochemistry and accumulated viral particles on electron microscopy. Reports have also indicated severe hyponatremia and hypokalemia in patients infected with SARS-CoV-2, possibly due to an inflammatory response pathologically causing electrolyte impairment secondary to non-osmotic release of vasopressin. A transtubular potassium gradient for this patient was scored as 8 indicating hypokalemia as a result of renal potassium wasting supporting the idea that SARS-CoV-2 renal damage was responsible for this patient’s electrolyte abnormalities. These findings lend support to the hypothesis that SARS-CoV-2 may directly induce renal damage.

AKI is an abrupt decrease in the GFR resulting in electrolyte disturbances, retained metabolic waste, and is a well-recognized complication of HIV. The symptoms of AKI are generally nonspecific apart from oliguria, making blood urea nitrogen (BUN) and creatinine essential for diagnosis. Diagnostic criteria for AKI are defined as either a 50% increase in serum creatinine from the patient’s baseline or a reduction in creatinine clearance by 50%. A strong correlation exists between the onset of AKI symptoms and the patient requiring intubation with mechanical ventilation. The rate of AKI in patients receiving mechanical ventilation was noted to be as high as 89.7% in some studies compared to that of patients not receiving mechanical ventilation which was 21.7%. Despite previous studies from Italy and China which determined the rate of AKI to be from 0.5% to 29%, with many studies demonstrating percentages on the lower end of the spectrum, the United States had an astronomical number of AKI cases. Since China and Italy had experienced surges in cases of Sars-CoV-2 prior to the United States, it is perplexing as to why the COVID-19 patients in the United States were more likely to suffer from renal injury. Various risk factors have been studied such as hypertension, diabetes mellitus type II, age as well as obesity; however, mechanical ventilation and the use of vasopressors demonstrate the strongest correlations in terms of risk of developing AKI.

Our patient was maintained on nasal cannula for the duration of his hospitalization and his hypotension was treated with fluid resuscitation instead of vasopressors. Although our patients’ baseline creatinine was unknown, his elevations in CK, electrolyte derangements, BUN, and acute clinical presentation were suggestive of AKI. AKI in HIV patients has a wide range of causes including prerenal azotemia, rhabdomyolysis, microangiopathy, glomerulonephritis, Hepatitis B or C, ATN, acute interstitial nephritis, crystal-induced nephropathy, nephrotoxicity from HAART, and HIV-associated nephropathy. ATN is an important cause to investigate in this patient particularly due to its association with AKI, COVID-19, and HIV. In our patient, his urinalysis only contained 3 RBC/hpf and no casts which made ATN, glomerulonephritis, microangiopathy, and crystal-induced nephropathy less likely. Thrombotic microangiopathy (TMA) has been noted in patients with COVID-19-induced AKI. Underlying complement disorders and gemcitabine use have been demonstrated as the potential causes of TMA in such patients. New data have shown that Sars-CoV-2 can activate the alternate and lectin pathways of the complement system resulting in an inflammatory response. The inflammation leads to the development of coagulopathy and subsequently TMA in some cases. It is a point of contention as to whether infection with COVID-19 is a secondary insult to patients with underlying predispositions to the development of TMA such as complement disorders or prior use of medications that have been associated with the development of TMA. While AKI in this patient can be attributed to his initial hypotension and hemodynamic instability resulting in decreased renal artery perfusion, it is crucial to consider that SARS-CoV-2 infection of the kidneys with subsequent replication in the renal tissue may have played a substantial role in the patients’ abrupt decline in renal function.

Rhabdomyolysis is a common cause of AKI among HIV-positive patients with an incidence reported to be of 943 per 100,000 person-years. Infection is most commonly identified as the precipitating etiology, particularly pneumonia which constitutes 38% of infectious causes. In the HIV population, rhabdomyolysis is associated with increased mortality compared to the rest of the population.
mechanisms including trauma, crush injuries, use of statins, cocaine, amphetamines, heroin, Phencyclidine, musculoskeletal diseases, hyperthermia, hypothermia, burns, muscular ischemia, hypophosphatemia, seizures, prolonged operations, and severe dehydration. The patient stated he had not experienced any trauma, seizures, temperature extremes, prolonged operations, burns, or crush injuries. The patient was screened for illicit drug use upon presentation which was negative and phosphate levels were elevated on presentation. Severe dehydration was the only potential cause apart from infection which was significant in this patient as a cause for rhabdomyolysis. Studies have demonstrated that COVID-19 has been known to cause hypotension in greater than 50% of cases. Whether directly through involvement of SARS-CoV-2 interaction with ACE-2 receptor or indirectly from causing hypotension from an undetermined mechanism, this patient’s decline in renal function can be attributed to his acute infection with COVID-19.

In a patient with HIV on HAART, it is important to consider the potential impact of therapy on both renal function and the patients’ ability to counter infections. Although HAART increases CD4+ counts and subsequently decreases the risk of certain infections, it is associated with an increased incidence of AKI from 2.9% to 6.0% in HIV patients. Despite the concern of AKI from HAART, 52% of all renal injury in HIV patients are primarily caused by infection. Delaying administration of HAART in HIV patients with AKI prevents further renal injury from the medications’ nephrotoxic nature.

Prior to discontinuation upon hospitalization, our patient’s HAART regimen consisted of lopinavir and ritonavir. The patient endorsed compliance with his HAART regimen prior to hospitalization. Lopinavir acts via inhibition of viral 3 chromotrypsin-like (3CL) proteases which has been hypothesized as the mechanism for efficacy against SARS-CoV-2 since 3CL proteases play a fundamental role in the processing of viral RNA which interferes with the viral replication process. Although the lopinavir/ritonavir combination drug has been investigated as a potential treatment regimen for COVID-19, there has been conflicting evidence in terms of efficacy. Some studies have reported a reduction of symptoms and SARS-CoV-2 viral load when initiated early in the treatment course. Despite the recommendation by early studies that lopinavir/ritonavir should be used in vulnerable populations with COVID-19 pneumonia, more evidence is needed to enforce this practice. Our patient’s exceptional clinical course despite having HIV lends to the idea that his HAART regimen as well as his azithromycin use prior to presentation may have decreased the total amount of SARS-CoV-2 viral replication in both the renal parenchyma and pulmonary tissue resulting in a rapid recovery and subsequent hospital discharge.

The potential of COVID-19 to antagonize renal function is crucial to note given most cases of both rhabdomyolysis and AKI in HIV patients are precipitated by infections. In the case presented, our patient had significantly elevated CK of 2185 U/L, with drastic elevations in creatinine and significant uremia. It is likely that the AKI in our patient was multifactorial involving direct tissue damage from SARS-CoV-2, COVID-19-induced hypotension, and indirect injury through another mechanism compounded by rhabdomyolysis.

Conclusion

In this report, we present a case of AKI in an HIV-positive patient with COVID-19 with a successful outcome. Clinicians should be cautious of this complication in HIV patients; those presenting with symptoms consistent with SARS-CoV-2 infection may be at an increased risk of AKI given they are immunocompromised. In our case, the damage to the kidney was likely a combination of pneumonia-induced rhabdomyolysis and direct effects of SARS-CoV-2 on renal parenchyma. The use of HAART therapy and azithromycin prior to admission may have been a contributing factor in the remarkably quick recovery of our patient.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

Our institution does not require ethical approval for reporting individual cases or case series.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent

Written informed consent was obtained from the patient(s) for their anonymized information to be published in this article.

ORCID iDs

Allison Foster https://orcid.org/0000-0001-5900-7969
Zohaib Khan https://orcid.org/0000-0002-1702-0388
Aisha Siddiqui https://orcid.org/0000-0002-9566-2618
Sukhdev Singh https://orcid.org/0000-0002-7922-9590

References

1. WHO. Novel Coronavirus 2019, https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (2019, accessed 17 April 2020).
2. Ronco C, Reis T and Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med 2020; 8(7): 738–742.
3. Batlle D, Soler MJ, Sparks MA, et al. Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology. J Am Soc Nephrol 2020; 31(7): 1380–1383.
4. Durvasula R, Wellington T, McNamara E, et al. COVID-19 and kidney failure in the acute care setting: our experience from Seattle. Ame J Kidney Diseases 2020; 76(1): 4–6.
5. World Health Organization: WHO. Coronavirus Who Int, https://www.who.int/health-topics/coronavirus#tab=tab_3 (2020, accessed 14 April 2020).
6. CDC. People who are at higher risk for severe illness. Centers for disease control and prevention, https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html (2020, accessed 14 April 2020).
7. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054–1062.
8. Wong HYF, Lam HYS, Fong AH-T, et al. Frequency and distribution of chest radiographic findings in COVID-19 positive patients. Radiology 2019; 296: E72–E78.
9. Luo E, Zhang D, Luo H, et al. Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China. Chin Med 2020; 15: 34.
10. Yao X, Li T, He Z, et al. Histopathology study of multiple coronavirus puncture in three patients with novel coronavirus pneumonia (COVID-19) [J / OL]. Chin J Pathol 2020; 49: 411–417.
11. Perico L, Benigni A and Remuzzi G. Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade. Nephron 2020; 144: 1–9.
12. Ye M, Wysocki J, William J, et al. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 2006; 17(11): 3067–3075.
13. Berni A, Malandrino D, Parenti G, et al. Hyponatremia, IL-6, and SARS-CoV-2 (COVID-19) infection: may all fit together? J Endocrinol Invest. Epub ahead of print 25 May 2020. DOI: 10.1007/s40618-020-01301-w.
14. Diao B, Wang C, Wang R, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. medRxiv. Epub ahead of print 6 March 2020. DOI: 10.1101/2020.03.04.20031120.
15. Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int 2020; 98(1): 209–218.
16. Liang SY and Overton ET. Renal and urologic emergencies in the HIV-infected patient. Emerg Med Clin North Am 2010; 28(2): 343–354, Table of Contents.
17. Sharma P, Uppal NN, Wanchoo R, et al. COVID-19-associated kidney injury: a case series of kidney biopsy findings. J Am Soc Nephrol 2020; 31: 1948–1958.
18. Wyatt CM, Arons RR, Klotman PE, et al. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 2006; 20(4): 561–565.
19. Zimmerman JL and Shen MC. Rhabdomyolysis. Chest 2013; 144(3): 1058–1065.
20. Kochi AN, Tagliari AP, Forleo GB, et al. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol 2020; 31(5): 1003–1008.
21. Koubar SH, Estrella MM, Warrier R, et al. Rhabdomyolysis in an HIV cohort: epidemiology, causes and outcomes. BMC Nephrol 2017; 18(1): 242.
22. Spiegel LR, Schrier PB and Shah HH. Severe recurrent rhabdomyolysis-induced acute kidney injury in a HIV-infected patient on antiretroviral therapy. Ren Fail 2013; 35(8): 1186–1190.
23. Kalim S, Szczech LA and Wyatt CM. Acute kidney injury in HIV-infected patients. Semin Nephrol 2008; 28(6): 556–562.
24. Baden LR and Rubin EJ. Covid-19—the search for effective therapy. N Engl J Med 2020; 382: 1851–1852.
25. Lopinavir ritonavir: A rapid review of effectiveness in COVID-19—CEBM. CEBM. https://www.cebm.net/covid-19/lopinavir-ritonavir-a-rapid-review-of-the-evidence-for-effectiveness-in-treating-covid/ (2020, accessed 17 April 2020).
26. Lim J, Jeon S, Shin H-Y, et al. Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 2020; 35(6): e79.